论文部分内容阅读
目的探究胎盘多肽注射液联合化疗治疗晚期胃癌患者的临床疗效。方法选取2012年6月至2014年6月间苏州大学附属第二医院收治的80例胃癌晚期患者,按照入院先后顺序随机分为治疗组与对照组,每组40例。对照组采用奥沙利铂联合替吉奥(SOX方案)常规化疗,治疗组在对照组基础上加用胎盘多肽注射液。比较两组患者治疗效果、生活质量评分、KPS功能评分和不良反应,同时检测CD3~+、CD4~+、CD8~+、CD4~+/CD8~+和NK细胞变化,并评估患者治疗前后免疫功能情况。结果治疗后,治疗组患者总有效率为45.0%,对照组为42.5%,两组比较,差异无统计学意义(P>0.05)。治疗前,两组患者生活质量评分比较,差异无统计学意义;治疗后,治疗组和对照组患者生活质量评分分别为(40.05±6.22)分和(27.05±6.57)分,两组比较,差异有统计学意义(P<0.05)。治疗后,治疗组患者KPS评分改善率为55.0%,对照组为32.5%,两组比较,差异有统计学意义(P<0.05)。治疗前,两组患者CD3~+、CD4~+、CD8~+、CD4~+/CD8~+和NK细胞等免疫指标比较,差异无统计学意义(P>0.05);治疗后,治疗组患者CD3~+、CD4~+、CD8~+、CD4~+/CD8~+和NK细胞分别为(65.37±7.68)%、(52.39±7.46)%、(28.49±6.21)%、(1.72±0.54)和(26.21±7.63)%,对照组患者分别为(58.45±6.27)%、(40.88±6.12)%、(33.46±7.04)%、(1.17±0.43)和(16.47±7.21)%,两组均较治疗前明显升高,且观察组升高幅度高于对照组,差异均有统计学意义(均P<0.05)。结论胎盘多肽注射液联合化疗治疗晚期胃癌,疗效显著,能够提高机体免疫功能,改善生活质量,降低化疗不良反应,值得临床推广。
Objective To investigate the clinical efficacy of placental peptide injection and chemotherapy in patients with advanced gastric cancer. Methods Eighty patients with advanced gastric cancer who were admitted to the Second Affiliated Hospital of Soochow University between June 2012 and June 2014 were randomly divided into treatment group and control group according to the order of admission, with 40 cases in each group. The control group was treated with oxaliplatin combined with conventional chemotherapy (SOX), and the treatment group was given the placental peptide injection on the basis of the control group. The therapeutic effect, quality of life score, KPS function score and adverse reactions were compared between the two groups. At the same time, the changes of CD3 +, CD4 +, CD8 +, CD4 + / CD8 + and NK cells were also measured. Functional situation. Results After treatment, the total effective rate was 45.0% in the treatment group and 42.5% in the control group. There was no significant difference between the two groups (P> 0.05). Before treatment, there was no significant difference in quality of life between two groups. After treatment, the scores of quality of life in treatment group and control group were (40.05 ± 6.22) and (27.05 ± 6.57) points respectively. There was no significant difference between the two groups There was statistical significance (P <0.05). After treatment, the improvement rate of KPS score was 55.0% in the treatment group and 32.5% in the control group, the difference was statistically significant (P <0.05). Before treatment, the immune indexes of CD3 ~ +, CD4 ~ +, CD8 ~ +, CD4 ~ + / CD8 ~ + and NK cells in the two groups had no statistical significance (P> 0.05) (65.37 ± 7.68)%, (52.39 ± 7.46)%, (28.49 ± 6.21)% and (1.72 ± 0.54)%, respectively. The percentage of CD4 ~ +, CD8 ~ +, CD4 ~ + / CD8 ~ And (26.21 ± 7.63)% in the control group were (58.45 ± 6.27)%, (40.88 ± 6.12)%, (33.46 ± 7.04)%, (1.17 ± 0.43) and (16.47 ± 7.21)%, Which was significantly higher than that before treatment, and the increase in observation group was higher than that in control group (all P <0.05). Conclusion Placenta polypeptide injection combined with chemotherapy for advanced gastric cancer has significant curative effect, which can improve the immune function, improve the quality of life and reduce the adverse reactions of chemotherapy, which is worthy of clinical promotion.